UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/552,110	07/03/2006	Robert Peter Millar	20747/300	4173

7590 11/14/2007

Nixon Peabody
Clinton Square
P.O. Box 31051
Rochester, NY 14603-1051

EXAMINER	
HA, JULIE	

ART UNIT	PAPER NUMBER
1654	

MAIL DATE	DELIVERY MODE
11/14/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/552,110	MILLAR, ROBERT PETER	
	Examiner	Art Unit	
	Julie Ha	1654	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *04 October 2007*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-11,13-33,35,37,39-41,43 and 45-60* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1-11,15-26,29-33,35,37,39-41, 43 and 45-60* is/are rejected.

7)☒ Claim(s) *13,14,27 and 28* is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☒ All b)☐ Some * c)☐ None of:

1.☒ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

Amendment after Non-Final filed on October 04, 2007 is acknowledged. Claim 12 has been cancelled. Claims 1-11, 13-33, 35, 37, 39-41, 43 and 45-60 are pending in this application. The requirement for election and restriction mailed on December 13, 2006 had been vacated in the previous office action. Claims 1-11, 13-33, 35, 37, 39-41, 43 and 45-60 are examined on the merits in this office action.

Julie Ha is the Examiner on record.

Withdrawn Objections

1. Claim objection to claims 9 and 11 are hereby withdrawn due to Applicant's amendment to claims.

Withdrawn Rejection

2. Claim rejection under 35 U.S.C. 112, 1st under lack of enablement is hereby withdrawn due to Applicant's amendment and arguments.

Maintained Rejections

35 U.S.C. 112, 1st

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:
> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 1-11, 15-26, 29-33, 35, 37, 39-41, 43 and 45-60 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement.

The claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. To provide evidence of possession of a Claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of compete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof.

5. Claims 1-11, 15-26, 29-33, 35, 37, 39-41, 43 and 45-60 are drawn to GnRH analogues conjugated to hormone moieties and their derivatives. The specification discloses the complete structure of GnRH analogues conjugated to a variety of steroid hormones. The claimed genus is much broader than this well-defined subgenus because the limitation hormone includes a large number of compounds that fall in entirely separate structural and functional classes.

6. A hormone is a chemical messenger from one cell (or group of cells) to another. All multicellular organisms produce hormones including plants. The function of hormones is to serve as a signal to the target cells, and the action of hormones is determined by the pattern of secretion and the signal transduction of the receiving tissue. The best-known animal hormones are those produced by endocrine glands of vertebrate animals, but hormones are produced by nearly every organ system and tissue type in a multicellular organism. The three major classes of hormones in humans include amine-derived hormones, peptides, and lipid-derived hormones.

7. Amine-derived hormones are derivatives of the amino acids tyrosine and tryptophan. Examples are melatonin, serotonin, triiodothyronine, epinephrine, norepinephrine, dopamine, corticotrophin-releasing hormone, catecholamines and thyroxine.

8. Peptide hormones consist of chains of amino acids ranging from less than 10 to over 100 amino acids in length. Each peptide hormone has a unique amino acid sequence that dictates its structure and function. Examples of peptide hormones include antimullerian hormone, adiponectin, adrenocorticotropic hormone, angiotensin, antidiuretic hormone, atrial-natriuretic, calcitronin, cholecystokinin, corticotropin-releasing hormone, erythropoietin, follicle-stimulating hormone, gastrin, ghrelin, glucagons, gonadotropin-releasing hormone, growth hormone- releasing hormone, human chorionic gonadotropin, human placental lactogen, growth hormone, inhibin, insulin, insulin-like growth factor, leptin, luteinizing hormone, melanocyte stimulating hormone, oxytocin, parathyroid hormone, prolactin, relaxin, secretin, somatostatin, thrombopoietin, thyroid-stimulating hormone, and thyrotropin-releasing hormone. More complex protein hormones bear carbohydrate side chains and include luteinizing hormone, follicle-stimulating hormone and thyroid-stimulating hormone.

9. Lipid-derived hormones are derivatives of lipids such as linoleic acid and arachidonic acid as well as phospholipids. The main classes of lipid-based hormones are the steroid hormones that are derived from cholesterol and the eicosanoids. Examples of steroid hormones are cortisol, aldosterone, testosterone, dehydroepiandrosterone, androstenedione, dihydrotestosterone, estradiol, estrone,

estriol, progesterone, calcitriol, and prostaglandins. Examples of eicosanoids are leukotrienes, prostacyclin and thromboxane.

10. Despite this breath, the specification only provides evidence that applicant was in possession of GNRH conjugated to steroid hormones at the time the invention was filed (see Figures 1A and 1B for example). Although other hormones are described in the prior art, their use in conjugation to GNRH is not known. The specification fails to describe in any detail how hormones other than steroid hormones can be conjugated to GNRH analogues while retaining the hormonal activity of GNRH and the plasma protein binding activity of the partner hormone. Given the diversity in sequence, size and tertiary structure of the peptide hormones, this is a complex problem. Despite this complexity, the specification fails to address for example how the GNRH analogue can be attached to the peptide hormone without disrupting the intended activities and functional characteristics. Furthermore, the specification fails to describe the use of peptide or amine hormones to prolong the half-life of GNRH in the bloodstream. Finally, the specification does not describe the plasma hormone binding proteins specific to hormones other than steroid hormones.

11. As broad as the genus hormone is, the genus hormone derivatives is even broader. The specification defines derivative of a hormone as a structure modified from the structure of the hormone found in nature that may or may not retain its hormonal activity but does retain its ability to bind to plasma hormone binding protein. The plasma hormone binding proteins described in the specification are globulins such as eortisol binding globulin, sex hormone binding globulin, progesterone binding globulin and

serum albumin. Steroid hormone derivatives that retain their ability to bind to these proteins are well-defined in the specification and include those which have been modified by adding a hydroxyl group at position 11, 17 or 21 such as 11- α-hydroxyprogesterones and 21-hydroxyprogesterones. The general relationship between structure and the function of binding to plasma hormone binding protein is also provided in the specification. For example, the specification states that in order to interact with sex hormone binding globulin, a steroid must contain a 17-β-hydroxyl group and that other features, such as the addition of a hydroxyl or a keto group at C 11 and modification of carbon 2, 6, 9 and 11 in the steroid nucleus have negative effects on binding affinity. In contrast, the specification fails to describe the structure, partial structure or guidance on the structure/function relationship for derivatives of hormones other than steroid hormones or even examples of plasma hormone binding protein specific to the amine-derived and peptide hormones.

12. Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116). With the exception of GNRH conjugated to steroid hormones and their derivatives, the skilled artisan cannot envision the detailed chemical structure of the GNRH conjugates. Therefore, only GNRH analogues conjugated to steroid hormones and their derivatives, but not the

full breadth of the claims, meet the written description provision of 35 U.S.C. § 112, first paragraph. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 U.S.C. § 112 is severable from its enablement provision (see page 1115).

Response to Applicant's Arguments

13. Applicant argues that Applicants have amended claims 1, 45 and 46 by further limiting the claims to recite the subgenus "steroid hormone moiety" and in view of the office action acknowledging that the specification provides descriptive support for using steroid hormones and their derivatives (see pp.4-5), that the rejection should be withdrawn.

14. Applicant's arguments have been fully considered, but have not been found persuasive because as mentioned by the Applicant, "steroid hormone moiety" is a subgenus. There are vast numbers of steroid hormones known in the art. According to previous office action, the Examiner stated that "steroid hormone derivatives that retain their ability to bind to these proteins are well-defined in the specification and include those which have been modified by adding a hydroxyl group at position 11, 17 or 21 such as 11-α-hydroxyprogesterones and 21-hydroxyprogesterones" (see p. 5, 12th paragraph, lines 6-9). Further, the Examiner indicated, "the general relationship between structure and function of binding to plasma hormone binding protein is also provided in the specification. For example, the specification states that in order to interact with sex hormone binding globulin, a steroid must contain 17-β-hydroxyl group

and that other features, such as the addition of a hydroxyl or a keto group at C11 and modification of carbon 2, 6, 9 and 11 in the steroid nucleus have negative effects on binding affinity" (see p. 5, 12th paragraph, lines 9-14). The specification discloses "typically, steroid hormones have either a hydroxyl group or a keto group at the 3 position. Many of the steroid hormones have either a hydroxyl group or a keto group at the 17th position. A number of the steroid hormones have a hydroxyl group at the 11 position. Some of the steroid hormones have a hydroxyl group at the 21 position" (see paragraph [0053]). Specification further discloses that "preferably, the steroid hormone moiety is estradiol, progesterone, cortisol, corticosterone, estrone, testosterone and dihydroxytestosterone (DHT)" (see paragraph [0054]). Further, the specification discloses that "derivatives of steroid hormones which are steroids but which no longer have hormonal activity may be used provided that they bind to a plasma hormone binding protein" (see paragraph [0056]). The specification discloses that "for example, as shown in Example 1, conjugation of a GnRH analogue to the 21 position of 21-hydroxyprogesterone maintains the progesterone activity in the conjugate compound. Conversely, if steroid hormone activity was to be eliminated, the GnRH could be conjugated to the keto group at the 3 position" (see paragraph [0064]). The specification does not describe any other steroid hormones than "estradiol, progesterone, cortisol, corticosterone, estrone, testosterone and DHT". However, the specification does not define a "steroid hormone" or a "steroid hormone derivatives". The specification discloses that "by derivatives of a hormone moiety we include the meaning that the derivative has been modified from the structure of the hormone moiety found in

nature..." and "derivatives of steroid hormones are steroids but which no longer have hormonal activity". However, there are vast numbers of steroid hormones and their derivatives, since different modification steps and different moieties can form derivatives. Therefore, rejection under 112, 1st paragraph written description is maintained.

Conclusion

15. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

16. A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

17. Claims 13, 14, 27 and 28 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

18. No claims are allowed.

19. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Julie Ha whose telephone number is 571-272-5982. The examiner can normally be reached on Mon-Fri, 8:00 am to 4:30 pm.

20. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

21. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Julie Ha
Patent Examiner
AU 1654

11/7/08
ANISH GUPTA
PRIMARY EXAMINER